Methylphenidate Treatment of Attention Deficits in Epilepsy

PHASE4CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

December 31, 2015

Conditions
EpilepsyCognitive DeficitsAttention Deficits
Interventions
DRUG

Methylphenidate

"Participants with epilepsy will first receive blinded, single-dose capsules which contain either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate.~At each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed."

Trial Locations (1)

94305

Stanford University, Palo Alto

All Listed Sponsors
lead

Kimford Jay Meador

OTHER

NCT02178995 - Methylphenidate Treatment of Attention Deficits in Epilepsy | Biotech Hunter | Biotech Hunter